Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study.
Teresa M SalgadoCaroline S QuinnEmily K KrumbachIris WenceslaoMartha GonzalezHolly L ReedJillian G SyversonRebecca S EtzKiran VangipuramMelissa R BarkerN Lynn HenryKaren B FarrisDaniel L HertzPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2020)
Despite the lack of evidence of CIPN withholding, women considered both the effectiveness and the toxicity of paclitaxel treatment, as well as beliefs about treatment and long-term consequences of CIPN and relationship with the oncology team, when deciding whether to report CIPN symptoms.